US20050202055A1 - Anti-wrinkle agent - Google Patents

Anti-wrinkle agent Download PDF

Info

Publication number
US20050202055A1
US20050202055A1 US10/932,097 US93209704A US2005202055A1 US 20050202055 A1 US20050202055 A1 US 20050202055A1 US 93209704 A US93209704 A US 93209704A US 2005202055 A1 US2005202055 A1 US 2005202055A1
Authority
US
United States
Prior art keywords
benzoic acid
skin
group
medicament
retinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/932,097
Other languages
English (en)
Inventor
Koichi Shudo
Seishiro Fujii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KEMPHYS Ltd
Koichi SHUDO Tokyo Japan
Original Assignee
Koichi SHUDO Tokyo Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koichi SHUDO Tokyo Japan filed Critical Koichi SHUDO Tokyo Japan
Assigned to SHUDO, KOICHI reassignment SHUDO, KOICHI ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FUJII, SEISHIRO, SHUDO, KOICHI
Publication of US20050202055A1 publication Critical patent/US20050202055A1/en
Assigned to R & R INC. reassignment R & R INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHUDO, KOICHI
Priority to US12/040,374 priority Critical patent/US8030360B2/en
Assigned to KEMPHYS LTD. reassignment KEMPHYS LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: R & R INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an anti-wrinkle agent. More specifically, the present invention relates to a medicament which reduces wrinkles on skin.
  • Retinol or retinal has been known to be effective against skin disorders such as wrinkles, warts, eczema, and dandruff (European Published Unexamined Patent Application No. 301033, U.S. Pat. No. 3,932,665, U.S. Pat. No. 4,934,114 and the like).
  • Retinoic acid has been known to reduce wrinkles (European Published Unexamined Patent Application No. 379367, Drugs and Aging, 2, pp. 7-13, 1992). This substance has been used in the United States as a medicament for a treatment of skin damaged from ray of sunlight. It is reported that wrinkles caused by aging can be treated with retinol, retinal, and retinoic acid (U.S. Published Unexamined Patent Application No. 2001/53347).
  • retinoic acid is highly irritative to skin and induces flare or inflammatory dermatitis. Therefore, development of an anti-wrinkle agent which is low epispastic has been desired.
  • retinoids is a general name for compounds which exert similar actions to those of retinoic acid or a part of the actions by binding to receptors that are essential for expression of the physiological actions of all-trans-retinoic acid or 9-cis-retinoic acid (three sub-types of each receptor are known to exist). Among them, some compounds have almost the same level of actions as that of retinoic acid or a higher level of actions. However, a skin irritative action generally increases in proportion to the level of the pharmacological actions (J. Med. Chem., 32, pp. 834-840, 1989).
  • An object of the present invention is to provide a medicament which reduces wrinkles on skin. More specifically, the object of the present invention is to provide a medicament which has reduced irritation to skin and excellent anti-wrinkle actions.
  • the present invention thus provides a medicament having an anti-wrinkle action, which comprises as an active ingredient a retinoid having a fundamental structure of a phenyl substituted carbamoyl benzoic acid or a phenyl substituted carboxamide benzoic acid.
  • the aforementioned medicament wherein the retinoid does not substantially bind to a retinoic acid receptor (RAR) sub-type ⁇ ;
  • the aforementioned medicament wherein the retinoid having the fundamental structure of a phenyl substituted carbamoyl benzoic acid or a phenyl substituted carboxamide benzoic acid is 4-(2,4-bistrimethylsilylphenylcarboxamide)benzoic acid or 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid.
  • a use of the retinoid having a fundamental structure of a phenyl substituted carbamoyl benzoic acid or a phenyl substituted carboxamide benzoic acid for the manufacture of the aforementioned medicament and a method for reducing wrinkles on skin which comprises a step of applying to skin the retinoid having a fundamental structure of a phenyl substituted carbamoyl benzoic acid or a phenyl substituted carboxamide benzoic acid.
  • the medicament of the present invention an excellent anti-wrinkle action, and is characterized to have more reduced skin irritative action than those of conventional medicaments such as retinoic acid.
  • FIG. 1 shows results of cumulative skin irritancy test (50 ppm application) of a retinoid on guinea pig skin (changes with date).
  • FIG. 2 shows results of cumulative skin irritancy test (50 ppm application) of a retinoid on guinea pig skin (the 9th day of application).
  • FIG. 3 shows results of the horny layer turnover test.
  • FIG. 4 shows results of cumulative skin irritancy in the horny layer turnover test.
  • FIG. 5 shows results of determination for RA and Am80 of parameter KSD which correlates to the depth of skin grooves.
  • FIG. 6 shows degrees of skin thickening by RA and Am80.
  • a retinoid having a fundamental structure of a phenyl substituted carbamoyl benzoic acid or a phenyl substituted carboxamide benzoic acid can be used.
  • Varieties of retinoids having a fundamental structure of a phenyl substituted carbamoyl benzoic acid or a phenyl substituted carboxamide benzoic acid are known.
  • the term “fundamental structure” means a main chemical structure to which one or more of any kinds of substituents bind.
  • the phenyl group which substitutes on a carbamoyl group or a carboxamide group preferably has one or more substituents.
  • a lower alkyl group can be used (in the specification, the term “lower” means about 1 to 6, preferably 1 to 4 carbon atoms).
  • the lower alkyl group a linear or branched alkyl group is preferred. More specifically, examples include methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, sec-butyl group, and tert-butyl group.
  • examples include a lower alkoxy group such as methoxy group, a halogen atom (as the halogen atom, any of fluorine, chlorine, bromine, and iodine atom may be used), and a lower alkyl substituted silyl group such as trimethyl silyl group.
  • a phenyl group substituted with 2 to 4 lower alkyl groups or a phenyl group substituted with 1 to 2 tri-lower alkyl silyl groups is preferred.
  • a phenyl group substituted with 2 to 4 alkyl groups or a phenyl group substituted with two trimethylsilyl groups is more preferred.
  • the two lower alkyl groups substituting on the aforementioned phenyl group may combine to form one or two, preferably one, 5- or 6-membered ring together with the ring constituting carbon atoms of the phenyl group to which the alkyl groups bind.
  • the ring thus formed may be saturated or unsaturated and may be substituted with one or more lower alkyl groups such as methyl group and ethyl group.
  • the above formed ring may be substituted with preferably two to four, more preferably two methyl groups.
  • two adjacent lower alkyl groups substituting on the phenyl group may preferably combine to form 5,6,7,8-tetrahydronaphthalene ring, 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene ring or the like.
  • retinoid means a class of compounds which exert similar actions to those of retinoic acid or a part of the actions by binding to receptors essential for expression of the physiological actions of all-trans-retinoic acid or 9-cis-retinoic acid, and the term means the above compounds having at least one or more retinoid-like actions such as cell differentiation action, cell proliferation-promoting action, and a life sustaining action.
  • Weather or not a compound is a retinoid can be easily judged by various methods described in M. Sporn et al., Retinoids, Academic Press, 1984.
  • Retinoids generally have a property of binding to a retinoic acid receptor (RAR).
  • retinoids used as active ingredients of the medicaments of the present invention are those binds to subtype ⁇ (RAR ⁇ ) and subtype ⁇ (RAR ⁇ ) of the RAR, and does not substantially bind to subtype ⁇ (RAR ⁇ ).
  • the bindings to the retinoic acid receptor subtypes can be easily verified by a method described in a publication (H. de The, and A. Dejean, “Retinoids, 10 years on”, Basel, Karger, pp. 2-9, 1991).
  • an example includes a compound represented by the following general formula (I): [wherein R 1 , R 2 , R 3 , R 4 , and R 5 each independently represents hydrogen atom, a lower alkyl group, or a lower alkyl substituted silyl group, and when any two adjacent groups of R 1 , R 2 , R 3 , R 4 , and R 5 are lower alkyl groups, the two groups may combine to form a 5- or 6-membered ring together with the carbon atoms on the benzene ring to which the groups bind (said 5- or 6-membered ring may have one or more alkyl groups), and X represents —CONH— or —NHCO—].
  • a linear or branched alkyl group having 1 to 6, preferably 1 to 4, carbon atoms may be used as the lower alkyl group represented by R 1 , R 2 , R 3 , R 4 , and R 5 .
  • methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, sec-butyl group, or tert-butyl group may be used.
  • substituents for example, hydroxy group, a lower alkoxy group, and a halogen atom can be exemplified.
  • the lower alkyl substituted-silyl group represented by R 1 , R 2 , R 3 , R 4 , and R 5 an example includes trimethylsilyl group.
  • any two adjacent lower alkyl groups selected from the group consisting of R 1 , R 2 , R 3 , R 4 , and R 5 may combine to form one or two, preferably one, 5- or 6-membered ring together with the carbon atoms on the benzene ring to which the groups bind.
  • the ring thus formed may be saturated, partially saturated, or aromatic, and the ring may have one or more alkyl group.
  • the alkyl group which may substitute on the ring a linear or branched alkyl group having 1 to 6, preferably 1 to 4, carbon atoms may be used.
  • methyl group, ethyl group or the like may be used, and the ring may be substituted with preferably 2 to 4, more preferably 4, methyl groups.
  • the benzene ring on which R 2 and R 3 substitute together with R 2 and R 3 may preferably form 5,6,7,8-tetrahydronaphthalene ring, 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene ring or the like.
  • examples include 4-(2,4-bistrimethylsilylphenylcarboxamide)benzoic acid (Am555s, J. Med. Chem., 33, pp. 1430-1437, 1990) and 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl]benzoic acid (Am80, Hashimoto, Y., Cell struct. Funct., 16, pp.
  • 4-(2,4-bistrimethylsilylphenylcarboxamide)benzoic acid Am555s, J. Med. Chem., 33, pp. 1430-1437, 1990
  • 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl]benzoic acid Am80, Hashimoto, Y., Cell struct. Funct., 16, pp.
  • a substance in a salt form as well as a compound in a free form can be used.
  • a hydrate or a solvate of the free form or the salt may also be used.
  • Types of the salt are not particularly limited, and for example, sodium salt or the like is preferred.
  • a retinoid as an active ingredient of the medicament of the present invention has one or more asymmetric carbon atoms depending on types of the substituents, stereoisomers such as optical isomer and diastereoisomer in a pure form, as well as any mixtures of the stereoisomers, racemates or the like may be used as an active ingredient of the medicament of the present invention.
  • the medicament of the present invention is effective as a medicament used for reducing wrinkles on skin.
  • Causes of wrinkles are not particularly limited. Wrinkles caused by aging are preferable targets of the medicament of the present invention.
  • the medicament of the present invention can apply to wrinkles caused by dermatopathies due to rays of sunlight or drugs, juvenile multi-wrinkle, and the like.
  • the routes of administration of the medicament of the present invention are not particularly limited.
  • the medicament can be administered orally or parenterally.
  • the medicament of the present invention one or more of substances selected from the group consisting of the aforementioned retinoids and salts thereof, and hydrates thereof and solvates thereof.
  • the aforementioned substance, per se may be administered.
  • the medicament can be administered as a pharmaceutical composition for oral or parenteral administration which can be prepared by a method well known to one of ordinary skill in the art.
  • pharmaceutical compositions suitable for oral administration examples include tablets, capsules, powders, subtle granules, granules, liquids, and syrups.
  • compositions suitable for parenteral administration examples include injections, suppositories, inhalant, eye drops, nasal drops, ointments, creams, and patches.
  • the medicament of the present invention is preferably applied parenterally to skin or mucous membrane as a pharmaceutical composition in a form of an external preparation for topical administration.
  • Types of pharmaceutical compositions in a form of external preparations are not particularly limited. For example, ointment, creams, lotions, and solutions can be exemplified.
  • the aforementioned pharmaceutical composition can be prepared by addition of physiologically and pharmacologically acceptable additives.
  • physiologically and pharmacologically acceptable additives examples include excipients, disintegrants or disintegration aids, binders, lubricants, coating agents, coloring agents, diluting agents, base materials, dissolving agents or dissolving aids, isotonizing agents, pH modifiers, stabilizers, propellants, and adhesives.
  • physiologically and pharmacologically acceptable additives examples include excipients, disintegrants or disintegration aids, binders, lubricants, coating agents, coloring agents, diluting agents, base materials, dissolving agents or dissolving aids, isotonizing agents, pH modifiers, stabilizers, propellants, and adhesives.
  • the pharmaceutical composition in a form of an external preparation can be formulated by using pharmaceutical additives generally used for external preparations and by a method well known to one of ordinary skill in the art. Types of the pharmaceutical additives are not particularly limited.
  • water soluble or oily polymer base materials for example, water soluble or oily polymer base materials, surfactants, pH modifiers, buffing agents, isotonizing agents, preservatives, thickeners, organic solvents such as ethanol can be exemplified.
  • amounts of the additives to be mixed are not particularly limited. Suitable amounts can be chosen depending on a type of formulation.
  • a dose of the medicament of the present invention is not particularly limited.
  • the dose may be suitably increased or decreased depending on various factors which should generally be taken into consideration, such as the body weight and age of a patient, the type and condition of a disease, the administration route, and the like.
  • the medicament can be used in a range of about 0.01 to 1,000 mg for oral administration per day for an adult, and the aforementioned dose may suitably be increased or decreased.
  • a dose of the medicament in a form of an external preparation is also not particularly limited.
  • the dose is about 1 pg to 1 mg per day as a dose for topical administration.
  • the dose can be suitably increased or decreased depending on conditions and the like.
  • Histological tests were conducted to study the irritancy of a retinoid on guinea pig skin and correlation between an irritancy threshold and a retinoid action threshold.
  • Each of male guinea pigs of approximately in a weight of 600 g was applied once every day with 1, 5, 10, 50, or 100 ppm of retinoic acid (RA) or Am80 (4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid) as an ethanol solution on the dorsal skin (5 days a week).
  • RA retinoic acid
  • Am80 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid
  • ethanol solvent
  • FIG. 1 The results are shown in FIG. 1 . Comparison of RA and Am80 at the same concentration revealed that Am80 induces much weaker skin response than retinoic acid and induces extremely slow skin response. Further, concentration dependencies of cumulative skin irritancy of RA and Am80 for the same application period were compared. As a result, RA irritancy threshold was less than 5 ppm and the irritancy was increased concentration dependently, whereas Am80 of 10 ppm or less induced no skin responses during this period ( FIG. 2 ). Table 1 shows results of a comparison of histological findings at the end of the application period. As compared with RA, Am80 caused more slight skin thickening and inflammatory changes even when applied at 10 times higher concentration.
  • the image analysis parameter KSD (the dispersion of luminance distribution in a 3.9 mm ⁇ 3.9 mm pixel), which correlates to the depth of skin grooves, was significantly decreased in the drug applied group ( FIG. 5 ). Further, the decrease in KSD correlated to epidermal thickening. Both of Am80 and RA gave obvious changes ( FIG. 6 ).
  • RA gave the maximum effect (40% promotion) at 10 ⁇ 6 M
  • Am80 gave the maximum effect (30% promotion) at 10 ⁇ 8 M.
  • the acceleration effect of Am80 (10%) was also observed at 10 ⁇ 10 Ml.
  • Am80 has a similar cell growth suppression action to that of RA.
  • IC 50 was 10 ⁇ 6 to 10 ⁇ 7 M for RA, and 10 ⁇ 9 M for Am80.
  • a cell differentiation suppression action of Am80 is stronger than that of RA, and also observed at a concentration as low as 10 ⁇ 8 to 10 ⁇ 10 M, and the suppression rates by Am80 were 1.3 to 1.7 times as compared to that by RA.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Coating Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US10/932,097 2004-03-11 2004-09-02 Anti-wrinkle agent Abandoned US20050202055A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/040,374 US8030360B2 (en) 2004-03-11 2008-02-29 Anti-wrinkle agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-068454 2004-03-11
JP2004068454 2004-03-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/040,374 Division US8030360B2 (en) 2004-03-11 2008-02-29 Anti-wrinkle agent

Publications (1)

Publication Number Publication Date
US20050202055A1 true US20050202055A1 (en) 2005-09-15

Family

ID=34918444

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/932,097 Abandoned US20050202055A1 (en) 2004-03-11 2004-09-02 Anti-wrinkle agent
US12/040,374 Expired - Fee Related US8030360B2 (en) 2004-03-11 2008-02-29 Anti-wrinkle agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/040,374 Expired - Fee Related US8030360B2 (en) 2004-03-11 2008-02-29 Anti-wrinkle agent

Country Status (8)

Country Link
US (2) US20050202055A1 (zh)
EP (1) EP1723952B1 (zh)
JP (1) JPWO2005087220A1 (zh)
KR (1) KR101151481B1 (zh)
CN (1) CN1946390B (zh)
AT (1) ATE447402T1 (zh)
DE (1) DE602005017473D1 (zh)
WO (1) WO2005087220A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040207055A1 (en) * 2003-02-21 2004-10-21 Yoshiro Iwasa Lead frame, semiconductor chip package, method for manufacturing semiconductor device, and semiconductor device
EP2969031A4 (en) * 2013-03-15 2017-03-08 Avisenna Cosmetics LLC Topical compositions for reducing aging effects

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019043865A (ja) * 2017-08-31 2019-03-22 ひまわり製薬株式会社 ざ瘡様疾患を治療又は予防するための皮膚外用組成物
AU2018341099B2 (en) 2017-09-28 2023-11-02 Johnson & Johnson Consumer Inc. Cosmetic compositions and method of treating the skin

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703110A (en) * 1984-07-07 1987-10-27 Koichi Shudo Benzoic acid derivatives having a para substituent which is a substituted phenyl group connected by a linking radical; useful in neoplastic cell differentiation and diagnosis
US4808631A (en) * 1986-11-07 1989-02-28 Hoffmann-La Roche Inc. Aromatic acid derivatives
US5081271A (en) * 1988-03-29 1992-01-14 Koichi Shudo Novel benzoic acid derivatives and process for preparing the same
US5216148A (en) * 1991-03-21 1993-06-01 Hoffmann-La Roche Inc. Carboxamides and anilides
US5750515A (en) * 1995-04-10 1998-05-12 Taiho Pharmaceutical Co., Ltd. Cancer metastasis inhibitor
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5807890A (en) * 1987-05-15 1998-09-15 Tristrata, Inc. Antiodor, antimicrobial and preservative compositions and methods of using same
US6004987A (en) * 1995-06-19 1999-12-21 Centre International De Recherches Dermatologiques Galderma Use of ligands which are specific for RXR receptors
US20010018456A1 (en) * 1995-10-09 2001-08-30 Laszlo Fesus Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis
US20040167215A1 (en) * 2003-01-17 2004-08-26 Deluca Hector F. Modified retinoid compounds and their uses
US20050085539A1 (en) * 2003-01-17 2005-04-21 Deluca Hector F. Method of reducing toxicity of retinoids

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932665A (en) 1974-04-05 1976-01-13 Scott Eugene J Van Process for the treatment of acne vulgaris utilizing retinal
JPS6176440A (ja) * 1984-09-19 1986-04-18 Koichi Shiyudo 安息香酸誘導体
JPS6122047A (ja) * 1984-07-07 1986-01-30 Koichi Shiyudo 安息香酸誘導体
US4934114A (en) 1986-08-27 1990-06-19 Lindsey Mfg. Co. Lightweight line tower kit
HU207654B (en) 1987-01-23 1993-05-28 Tibor Bagits Trowable device particularly for external fixing the fractures of small tubular bones
MY106263A (en) * 1989-01-19 1995-04-29 Ortho Pharma Corp Method for the treatment or prevention of intrinsically aged skin with retinoids
JP2761023B2 (ja) * 1989-03-20 1998-06-04 大鵬薬品工業株式会社 新規安息香酸誘導体及びその製造方法
US5093360A (en) 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
DE69728986T2 (de) * 1996-06-21 2005-04-07 Allergan, Inc., Irvine Substituierte tetrahydronaphthalin- und dihydronaphthalin-derivate mit einer retinoiden und/oder retinoid antagonist-ähnlichen biologischen aktivität
EP1005333B1 (en) 1997-02-25 2005-01-12 The Regents Of The University Of Michigan Methods and compositions for preventing and treating chronological aging in human skin

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703110A (en) * 1984-07-07 1987-10-27 Koichi Shudo Benzoic acid derivatives having a para substituent which is a substituted phenyl group connected by a linking radical; useful in neoplastic cell differentiation and diagnosis
US4808631A (en) * 1986-11-07 1989-02-28 Hoffmann-La Roche Inc. Aromatic acid derivatives
US5807890A (en) * 1987-05-15 1998-09-15 Tristrata, Inc. Antiodor, antimicrobial and preservative compositions and methods of using same
US5081271A (en) * 1988-03-29 1992-01-14 Koichi Shudo Novel benzoic acid derivatives and process for preparing the same
US5155249A (en) * 1988-03-29 1992-10-13 Koichi Shudo Benzoic acid derivatives and process for preparing the same
US5216148A (en) * 1991-03-21 1993-06-01 Hoffmann-La Roche Inc. Carboxamides and anilides
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5750515A (en) * 1995-04-10 1998-05-12 Taiho Pharmaceutical Co., Ltd. Cancer metastasis inhibitor
US6004987A (en) * 1995-06-19 1999-12-21 Centre International De Recherches Dermatologiques Galderma Use of ligands which are specific for RXR receptors
US20010018456A1 (en) * 1995-10-09 2001-08-30 Laszlo Fesus Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis
US20040167215A1 (en) * 2003-01-17 2004-08-26 Deluca Hector F. Modified retinoid compounds and their uses
US20050085539A1 (en) * 2003-01-17 2005-04-21 Deluca Hector F. Method of reducing toxicity of retinoids

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040207055A1 (en) * 2003-02-21 2004-10-21 Yoshiro Iwasa Lead frame, semiconductor chip package, method for manufacturing semiconductor device, and semiconductor device
EP2969031A4 (en) * 2013-03-15 2017-03-08 Avisenna Cosmetics LLC Topical compositions for reducing aging effects
US11039995B2 (en) 2013-03-15 2021-06-22 Samson Pharma, Llc Topical compositions for reducing the effects of aging

Also Published As

Publication number Publication date
EP1723952B1 (en) 2009-11-04
KR20070010146A (ko) 2007-01-22
EP1723952A1 (en) 2006-11-22
EP1723952A4 (en) 2007-10-03
CN1946390A (zh) 2007-04-11
JPWO2005087220A1 (ja) 2008-01-24
KR101151481B1 (ko) 2012-05-30
US20080153781A1 (en) 2008-06-26
US8030360B2 (en) 2011-10-04
DE602005017473D1 (de) 2009-12-17
WO2005087220A1 (ja) 2005-09-22
ATE447402T1 (de) 2009-11-15
CN1946390B (zh) 2011-04-27

Similar Documents

Publication Publication Date Title
US5981586A (en) Methods for treating proliferative and inflammatory skin diseases
DE69423782T2 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
US10137140B2 (en) Therapeutic composition
US8729052B2 (en) Composition for the prevention and treatment of alopecia, or for hair growth
JP2002275095A (ja) レチノイド皮膚損傷の抑制方法
WO2012148174A2 (ko) 탈모방지 및 발모촉진용 외용제 조성물
KR20100051808A (ko) 안드로겐 수용체 분해 강화제를 포함한 조성물 및 탈모와 피부질환의 예방 또는 치료 방법
US8030360B2 (en) Anti-wrinkle agent
EP0980243A1 (en) Use of high dose retinoids for the treatment of skin disorders
EP0790053B1 (fr) Utilisation d'un 2-amino-alcane-1,3-diol pour freiner la chute des cheveux et/ou induire et stimuler leur croissance
CN110831601A (zh) 三部分组成的雄激素受体消除剂、其方法和用途
JPH092952A (ja) セラミド合成促進剤
EP0829256A1 (fr) Utilisation d'un agoniste des récepteurs des rétinoides de type RXR pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
JP2021527634A (ja) Ｄｇａｔ１阻害剤の局所製剤およびそれらの使用の方法
JP2022541013A (ja) 肝臓ｘ受容体アゴニストでマイボーム腺機能不全を治療するための方法
US20190275022A1 (en) Methods, compositions, and compounds for treatment of dermatological and ocular conditions
KR20110074890A (ko) 탈색소 국부 조성물 및 이의 용도
JP2002047178A (ja) Ｉ型マトリックスメタロプロテアーゼ産生阻害剤
JP3827259B2 (ja) 表皮角質化促進剤
EP1739083A1 (fr) Composés benzylidène-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres kératiniques et/ou freiner leur chute et/ou augmenter leur densité.
US20110046234A1 (en) Retinaldehyde in the Treatment of Obesity, Diabetes and Other Conditions
KR101373714B1 (ko) 각화막 형성 촉진용 화장료 조성물
KR101373715B1 (ko) 각화막 형성 촉진용 화장료 조성물
WO2011006504A2 (en) Treatment of hyperproliferative conditions
WO2024013741A1 (en) Topical tapinarof composition for treating skin disorders

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHUDO, KOICHI, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHUDO, KOICHI;FUJII, SEISHIRO;REEL/FRAME:016114/0308

Effective date: 20041210

AS Assignment

Owner name: R & R INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHUDO, KOICHI;REEL/FRAME:018634/0808

Effective date: 20061128

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: KEMPHYS LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:R & R INC.;REEL/FRAME:023369/0996

Effective date: 20090924